Director, Atavistic Chemotherapy Clinical Trial
Former Assistant Professor of Oncology,
and Pediatrics, Hematology and Oncology,
University of Rochester School of Medicine and Dentistry. Rochester, NY.
Former Senior Scientist, Division of Cancer Treatment & Diagnosis,
National Cancer Institute, National Institutes of Health. Frederick, MD.
In Scientific Collaboration with his Brothers.......
Important: This clinical study is registered with the National Institutes of Health (USA) under the identifier: NCT02366884 (www.clinicaltrials.gov). This study was initiated in 2011, and it is NOT being sponsored by any pharmaceutical company or cancer organization. It has been financed and sponsored in its entirety by the Arguello brothers. This is a not-for-profit activity, and patients pay only for the cost of the drugs involved in their treatment and services ($1,500 USD/month) when they can afford to do so. Participating patients have been from the U.S. or Canada. About 70 percent of patients have been treated for free or for a nominal charge since they came from countries with smaller economies (Mexico, Greece, etc.).
Question for You: If a non-toxic and effective way to cure inoperable or metastatic cancer is discovered, do you think that discovery is going to come from the ideas and drugs we have been using unsuccessfully for the last 70 years, or will it come from new concepts in tumor cell biology and very different types of drugs than the ones we have been using without success for so long? What do you think?
Unfortunately, up to 80 percent of patients with lethal metastatic cancers erroneously believe that they can be cured with current treatments, when in reality, they all die. Ref: http://www.webmd.com/cancer/news/20121024/incurable-cancer-patients-think-cure
IMPORTANT FACTS ABOUT CANCER YOU MUST KNOW IN ORDER TO AVOID THE SAME MISTAKE: Almost all types of cancers are curable, as long as they are removed completely with surgery when the tumor is still localized in the organ of origin. Likewise, almost all cancers are invariably lethal if they have escaped curability with surgery (have spread to distant organs [metastasized] or are technically inoperable). These facts have remained unchanged for the last 200 years for all common cancers that affect humans (brain tumors, melanomas, sarcomas, and lung, breast, colon, stomach, prostate, pancreatic, skin, liver, kidney, ovarian, uterine, and cervical cancers to name a few). Curable leukemias, lymphomas, and testicular cancers account for less than 3 percent of all cancers.
Frequently, we have been told, that if this treatment was as good as we say, then hospitals everywhere would be rushing to use it. Nothing could be further from the truth. Contrary to what most people believe, a non-toxic, inexpensive, and effective treatment for cancer is not welcomed by the oncological community. Why is that? Simply put, doctors and scientists alike do not want to believe that they have misunderstood tumor cell biology and have been treating cancer improperly for close to 70 years. Additionally, cancer has become a very profitable medical practice and an important business for the pharmaceutical industry.
Let me offer a few actual examples of how inopportune our treatment of cancer would be for cancer hospitals and the pharmaceutical industry.
First, the not-for-profit academic institution of the MD Anderson Cancer Center in Houston, Texas makes $4.4 billion dollars in revenue annually. About 70 percent of that amount comes from payments for treating cancer patients, while the rest is from donations, grants, the government of Texas, etc. Ref: http://www.mdanderson.org/about-us/facts-and-history/quick-facts/index.html. Similarly, at least six of 20 administrators of the not-for-profit Sloan Kettering Cancer Institute have salaries between $1–2 million per year. The rest make above half a million in salary. Ref: http://healthland.time.com/2013/02/21/the-profit-of-prestigious-cancer-care/
In 2010 and 2011, the FDA approved a drug called Provenge®, developed by Dendreon of Seattle, which purports to train the immune system to fight prostate cancer. Also approved by the FDA was Yervoy®, Bristol-Myers Squibb's drug to treat melanoma. Provenge® costs $93,000 for a course of treatment, yet it only extends life by an average of four months. Yervoy® costs $120,000 per course, and it extends life by an average of three and a half months. Ref: http://www.economist.com/node/18743951
So, who would want to disrupt that flow of money with a therapy that does not even require a hospital stay? YOU — those who have metastatic or inoperable cancer and want to survive the disease. You are the ones who should be interested in this new form of therapy. We are 100 percent certain that this form of treatment is going to change the practice of oncology forever. We have witnessed results never seen before in the history of medicine (see images here). Therefore, sooner or later, the patient population will demand a change, even if that means financial losses for hospitals and the pharmaceutical industry. Your life is priceless!
Finally, none of this means that the MD Anderson Cancer Center, the Sloan Kettering Cancer Institute, and the pharmaceutical industry do not want a cure for cancer. Of course, they hope to develop a cure — within their current belief systems, research plans, and profitable medical practices. That could never happen because the current concepts on tumor cell biology are erroneous, and people are paying high costs for drugs that do not work. A radical change in the science and treatment of cancer is needed. Current treatments for cancer will soon be seen as barbaric, and cancer surgeries as unnecessary mutilations, leaving women without breasts and other patients disfigured. Can we do better? Yes, but we need the participation of the cancer patient community. Help us to make that change!
Would you like to stay informed about Dr. Arguello’s research, new clinical cases and information updates? Enter your email below to receive our newsletter.